文献速递妇科肿瘤

铂敏感复发卵巢癌进展后继续贝伐珠单抗联合卡铂双药III期试验

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2021-01-01

这项开放标签随机III期试验纳入406例一线含贝伐珠单抗治疗后铂敏感复发的卵巢癌患者,比较卡铂双药联合贝伐珠单抗与卡铂双药单药的疗效。

要点

  • 进展后继续贝伐珠单抗联合化疗显著改善铂敏感复发卵巢癌的无进展生存期
  • 联合组高血压3-4级发生率29%,高于标准化疗组的10%

核心结论

  • 在铂敏感复发卵巢癌患者中,进展后继续贝伐珠单抗联合化疗较单纯标准化疗显著改善无进展生存期,可考虑用于临床实践。

研究设计与样本

  • 开放标签、随机、III期试验,在4个国家82个中心开展,纳入406例既往一线含贝伐珠单抗治疗的铂敏感复发(距末次铂剂≥6个月)FIGO IIIB-IV期卵巢癌患者,ECOG 0-2,按1:1随机分配。

主要发现

  • 标准化疗组161例(79%)进展,贝伐珠单抗组143例(70%)进展。
  • 最常见3-4级不良事件:高血压标准化疗组20例(10%)vs贝伐珠单抗组58例(29%),中性粒细胞减少81例(41%)vs80例(40%),血小板减少43例(22%)vs61例(30%)。
  • 标准化疗组68例(33%)死亡,贝伐珠单抗组79例(39%)死亡;治疗相关死亡分别为2例(1%)和1例(<1%)。

临床怎么用

  • 对于一线含贝伐珠单抗治疗后铂敏感复发的卵巢癌患者,可考虑在二线卡铂双药化疗基础上继续联合贝伐珠单抗以延长无进展生存期。
  • 联合贝伐珠单抗时需注意高血压等3-4级不良事件的发生率增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bevacizumab is approved in combination with chemotherapy for the treatment of ovarian cancer, either in first-line therapy or for patients with recurrent disease not previously treated with the same drug. We aimed to test the value of continuing bevacizumab beyond progression after first-line treatment with the same drug. METHODS: In our open-label, randomised, phase 3 trial done at 82 sites in four countries, we enrolled women (aged ≥18 years) who had previously received first-line platinum-based therapy including bevacizumab, and had recurrent (≥6 months since last platinum dose), International Federation of Gynaecology and Obstetrics stage IIIB-IV ovarian cancer with an Eastern Cooperative Oncology Group performance status 0-2. Patients were randomly assigned (1:1) to receive a carboplatin-based doublet intravenously (carboplatin area under the concentration curve [AUC] 5 on day 1 plus paclitaxel 175 mg/m2 on day 1, every 21 days; carboplatin AUC 4 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8, every 21 days; or carboplatin AUC 5 on day 1 plus pegylated liposomal doxorubicin 30 mg/m2 on day 1, every 28 days), or a carboplatin-based doublet plus bevacizumab (10 mg/kg intravenous every 14 days combined with pegylated liposomal doxorubicin-carboplatin, or 15 mg/kg every 21 days combined with gemcitabine-carboplatin or paclitaxel-carboplatin). Evaluable disease according to RECIST 1.1 guidelines was required before randomisation. Randomisation was done through the trial website with a minimisation procedure, stratified by centre, time of recurrence, performance status, and type of second-line chemotherapy. The primary endpoint was investigator-assessed progression-free survival, analysed on an intention-to-treat basis. Safety was assessed in all participants who received at least one dose. This trial is registered with ClinicalTrials.gov, NCT01802749 and EudraCT 2012-004362-17. FINDINGS: Between Dec 6, 2013, and Nov 11, 2016, 406 patients were recruited (203 [50%] assigned to the bevacizumab group and 203 [50%] to the standard chemotherapy group). 130 patients (64%) in the bevacizumab group and 131 (65%) in the standard chemotherapy group had progressed after receiving a last dose of platinum more than 12 months before, and 146 patients (72%) in the bevacizumab group and 147 (72%) in the standard chemotherapy group had progressed after completion of first-line bevacizumab maintenance. 161 participants (79%) progressed in the standard chemotherapy group, as did 143 (70%) in the bevacizumab group. Median progression-free survival was 8·8 months (95% CI 8·4-9·3) in the standard chemotherapy group and 11·8 months (10·8-12·9) in the bevacizumab group (hazard ratio 0·51, 95% CI 0·41-0·65; log-rank p<0·0001). Most common grade 3-4 adverse events were hypertension (20 [10%] in the standard chemotherapy group vs 58 (29%) in the bevacizumab group), neutrophil count decrease (81 [41%] vs 80 [40%]), and platelet count decrease (43 [22%] vs 61 [30%]). 68 patients (33%) died in the standard chemotherapy group and 79 (39%) died in the bevacizumab group; two deaths (1%) in the standard chemotherapy group and one death (<1%) in the bevacizumab group were deemed to be treatment-related. INTERPRETATION: Continuing bevacizumab beyond progression combined with chemotherapy in patients with platinum-sensitive recurrent ovarian cancer improves progression-free survival compared with standard chemotherapy alone and might be considered in clinical practice. FUNDING: Hoffmann-La Roche and Associazione Italiana per la Ricerca sul Cancro.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Pignata S, Lorusso D, Joly F, et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021. PMID: 33539744. doi:10.1016/S1470-2045(20)30637-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。